N/A N=37 DEFLECT I: Keystone Heart Embolic Deflection Trial
Aortic Stenosis
Primary: Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance) — 33 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants
N/A N=93 The Medtronic TAVR 2.0 US Clinical Study
Aortic Valve Stenosis
Primary: All-cause Mortality Rate — 1.7 percentage of participants
N/A N=54 Home-Based Exercise Program For Recovery After Transcatheter Aortic Valve Replacement
Aortic Valve Stenosis
Primary: Change in the Late-Life Function and Disability Instrument (LLFDI) Score — 53.2; 52.0; 52.9; 58.9 units on a scale
N/A N=349 WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
Atrial Fibrillation · Aortic Valve Stenosis
Primary: Composite of All-cause Mortality, Stroke and Bleeding — 60; 64 Participants
N/A N=218 PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)
Aortic Valve Stenosis
Primary: Number of Deaths — 16 Participants
Phase 3 N=231 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Aortic Valve Stenosis · Cardiovascular Diseases · Heart Valve Diseases
Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01
N/A N=90 NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial
Valvular Heart Disease · Aortic Valve Failure
Primary: Number of Participant That Experienced Technical Success With the TELLTALE Guidewire System — 90 Participants
N/A N=30 Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation
Native and Valve in Valve Aortic Valve Failure
Primary: Number of Participants With Procedure Success, Measured at Exit From the Catheterization Laboratory — 28 participants
N/A N=222 Portico TAVI Implant With Transfemoral Delivery System
Symptomatic Aortic Stenosis
Primary: All Cause Mortality — 8 Participants
N/A N=67 TEE 3D RV Assessment for SAVR, Mini AVR, and TAVR
Right Ventricular Dysfunction
Primary: 3D RVEF (Baseline) — 44.71; 48.74; 49.11 percentage — p=0.0167
N/A N=1,022 Aortic Valve Replacement With Trifecta(TM)
Aortic Valve Insufficiency · Regurgitation, Aortic Valve · Aortic Valve Incompetence
Primary: Late Adverse Event Rates — 1.90; 0; 2.61; 0.12 percentage of events/late patient years
N/A N=934 Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
Aortic Valve Stenosis · Aortic Valve Stenosis With Insufficiency · Regurgitation, Aortic Valve
Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…
N/A N=250 REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System
Transcatheter Aortic Valve Replacement
Primary: Primary Device Performance Endpoint: Mean Aortic Valve Pressure Gradient at 30 Days Post Implant Procedure — 11.45 mmHG
N/A N=197 PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve
Aortic Stenosis · Cardiomyopathy, Hypertrophic
Primary: Number of Participants With All-Cause Mortality, All Stroke, Moderate or Severe Obstruction, or Moderate or Severe Paravalvular Leak (Composite) — 28 Participants
N/A N=634 CoreValve® System Australia/New Zealand Clinical Study
Aortic Valve Stenosis
Primary: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate — 0.099 probability of events at 30 days
N/A N=211 PREVAIL-TF: Transfemoral Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)
Aortic Valve Stenosis
Primary: Number of Deaths — 21 Participants
N/A N=241 Medtronic CoreValve Evolut R U.S. Clinical Study
Aortic Stenosis
Primary: All-cause Mortality at 30 Days by Percent — 2.5 percentage of partcipants
N/A N=1,057 THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial
Critical Aortic Stenosis
Primary: Death — 84; 89; 55; 89 participants
N/A N=560 The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B
Severe · Symptomatic · Calcific Aortic Stenosis
Primary: Number of Participants With All-Cause Mortality and/or Major Stroke and/or Rehospitalization — 105; 102 participants
N/A N=100 ADVANCE Direct Aortic Study
Aortic Stenosis · Valvular Heart Disease
Primary: All-cause Mortality — 4.4 Percentage of subjects
N/A N=64 PREVAIL-J - Transfemoral & Transapical Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Japan)
Aortic Valve Stenosis
Primary: Improvement of the AVA and NYHA Functional Classification — 38.2; 45.8 % of participants
N/A N=91 Mitral Implantation of TRAnscatheter vaLves
Mitral Valve Disease
Primary: Technical Success at Exit From the Cath Lab. — 23; 20; 30 Participants
N/A N=2,032 PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk
Symptomatic Severe Aortic Stenosis
Primary: All-cause Death or Disabling Stroke to Two Years — 192; 202 Participants
N/A N=64 Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access
Aortic Valve Stenosis
Primary: Number of Participants With Major Vascular Complications — 2; 1 Participants
Phase 3 N=15 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)
Tricuspid Regurgitation
Primary: Procedural Success — 42.86 Percentage of Participants
N/A N=17 PREVAIL-20J - Transfemoral Placement of 20mm Aortic Balloon Expandable Transcatheter Valve Trial
Aortic Valve Stenosis
Primary: NYHA Improvement and AVA >= 0.65 cm2 — 14 Participants
N/A N=189 Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement
Transcatheter Aortic Valve Implantation
Primary: Post Procedure Hospital Length of Stay — 4.8; 3.5 days
N/A N=18 Medtronic CoreValve REDO Study
Aortic Valve Stenosis
Primary: Percentage of MAE Free Subjects — 10 Participants
N/A N=295 Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve
Aortic Valve Stenosis With Insufficiency · Aortic Valve Stenosis
Primary: Percent of Early Adverse Events — 1.7; 1.0; 4.5; 0.0 Percentage of subjects